MindMed Joins Critical Path Institute’s Patient-Reported Outcome Consortium

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD ),, a leading biotech company developing psychedelic-inspired therapies, has joined the Critical Path Institute’s (“C-Path’s”) Patient-Reported Outcome (PRO) Consortium to assist in the development of new approaches to advance medical innovation and regulatory science. C-Path ( www.c-path.org ) has multiple active consortia and programs that leverage knowledge sharing to spur innovation.

Read the source article at PR Newswire
2021-08-17 15:30:00